Hematologic Oncology Update, Issue 1, 2016 (Video Program)Brentuximab vedotin as consolidation therapy for patients with HL at high risk of disease progression after autologous stem cell transplant (ASCT)
0:53 minutes.
TRANSCRIPTION:
DR YOUNES: There’s like specific indications for the use of brentuximab per the AETHERA protocol. So this mainly targeted patients who are at high risk of relapse using a specific prognostic model. So patients who fail to achieve a CR, PET-negative status before going into transplant, then they would benefit from brentuximab vedotin as maintenance. Patients who had primary refractory disease that also would benefit. And patients who had residual disease — again, not achieving a CR postautologous transplant or had extranodal disease pretransplant — all those would qualify for brentuximab vedotin maintenance therapy, a la AETHERA trial. DR LOVE: Is that what you’re doing, again, outside a protocol setting in your practice? DR YOUNES: So it’s an option. Of course some patients are qualified for this, and they get an option. Some patients want to just take a break and say, “When I progress, I’ll take it.” So it’s an option. |